Omnicell (NASDAQ:OMCL) Rating Lowered to “Hold” at Zacks Research

Posted by Stanley Muller on Jul 9th, 2026

Omnicell (NASDAQ:OMCL – Get Free Report) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities analysts also recently commented on the company. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. KeyCorp raised their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Craig Hallum reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a report on Wednesday, April 29th. UBS Group set a $60.00 price target on Omnicell and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Benchmark reissued a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Omnicell presently has an average rating of “Moderate Buy” and a consensus price target of $59.86.

View Our Latest Report on OMCL

Omnicell Stock Up 1.7%

OMCL stock opened at $45.12 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The firm has a 50-day moving average of $42.20 and a two-hundred day moving average of $41.50. Omnicell has a 12 month low of $26.84 and a 12 month high of $55.00. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 102.55, a PEG ratio of 1.15 and a beta of 0.96.

Omnicell (NASDAQ:OMCL – Get Free Report) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to analysts’ expectations of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts forecast that Omnicell will post 1.31 earnings per share for the current fiscal year.

Insider Activity at Omnicell

In related news, EVP Nnamdi Njoku sold 3,090 shares of the stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares of the company’s stock, valued at approximately $6,689,807.70. This trade represents a 1.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of Omnicell stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This trade represents a 4.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently modified their holdings of the company. Dana Investment Advisors Inc. acquired a new position in Omnicell in the 4th quarter valued at about $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Omnicell by 71.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock worth $6,343,000 after purchasing an additional 58,193 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of Omnicell by 83.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 258,231 shares of the company’s stock worth $11,698,000 after purchasing an additional 117,556 shares in the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Omnicell during the fourth quarter worth about $4,804,000. Finally, Teachers Retirement System of The State of Kentucky boosted its stake in shares of Omnicell by 96.3% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock valued at $1,174,000 after purchasing an additional 12,713 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

(Get Free Report)

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.